Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status

Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy. Our study included 62 Caucasian advanced-stage non-small cell lung cancer (NSCLC) patients treated with a...

Full description

Saved in:
Bibliographic Details
Main Authors: David Dora, Balazs Ligeti, Tamas Kovacs, Peter Revisnyei, Gabriella Galffy, Edit Dulka, Dániel Krizsán, Regina Kalcsevszki, Zsolt Megyesfalvi, Balazs Dome, Glen J. Weiss, Zoltan Lohinai
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Anti-PD1 immunotherapy
gut microbiome
metagenome pathways
NSCLC
PD-L1
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204746
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204746

Similar Items